Sign in

Private company

CONTRAFECT Corp

American pharmaceutical preparations company based in Yonkers2

In its 2023 annual report the company says: “We are a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Our first DLA product candidate, exebacase, is currently being studied in an ongoing Phase 1b/2 study in patients with chronic prosthetic joint infections of the knee due to S. aureus or coagulase-negative Staphylococci.”60

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations2
  • HeadquartersYonkers, United States2
  • Incorporated inDE3
  • Business address28 Wells Avenue, 3Rd Floor, Yonkers, Ny 107013
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300JM7MIET5QG2X152
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O Corporation Service Company, 19808 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 45141372

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income45678-$64.6M in 2022+93% since 2016
-$80.0M-$60.0M-$40.0M-$20.0M02016: -$33.5M-$33.5M20162017: -$26.6M-$26.6M2017−21%2018: -$31.1M-$31.1M2018+17%2019: -$27.9M-$27.9M2019−10%2020: -$34.2M-$34.2M2020+23%2021: -$47.3M-$47.3M2021+38%2022: -$64.6M-$64.6M2022+37%
Net income45678-$65.2M in 2022+128% since 2016
-$80.0M-$60.0M-$40.0M-$20.0M02016: -$28.5M-$28.5M20162017: -$15.5M-$15.5M2017−46%2018: -$37.7M-$37.7M2018+143%2019: -$12.8M-$12.8M2019−66%2020: -$28.2M-$28.2M2020+120%2021: -$20.3M-$20.3M2021−28%2022: -$65.2M-$65.2M2022+221%
Fiscal year20162017201820192020202120222023
Research and development$22.1M4$17.3M5$22.4M6$18.1M7$22.6M8$35.5M8$44.7M8
Operating expenses$47.3M8$64.6M8
Operating income-$33.5M4-$26.6M5-$31.1M6-$27.9M7-$34.2M8-$47.3M8-$64.6M8
Interest
Net income-$28.5M4-$15.5M5-$37.7M6-$12.8M7-$28.2M8-$20.3M8-$65.2M8
Earnings per share-$98.958-$44.128-$124.978-$0.6911
Earnings per share (diluted)-$98.958-$44.128-$124.978-$0.6911
Shares (weighted, basic)459.7K shares8521.4K shares82.0M shares11
Shares (weighted, diluted)459.7K shares8521.4K shares82.0M shares11

Compare CONTRAFECT Corp with another company

Corporate structure

CONTRAFECT Corp sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of CONTRAFECT Corp

  • CONTRAFECT Corp Yonkers, New York, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What CONTRAFECT Corp reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$4.3M8 Dec 31, 2022$4.3M8 Dec 31, 2021+0.9%
Accumulated depreciation$3.7M8 Dec 31, 2022$3.6M8 Dec 31, 2021+4.3%
Property and equipment, net$627.0K8 Dec 31, 2022$741.0K8 Dec 31, 2021−15.4%
Operating-lease assets (leased space)$2.2M8 Dec 31, 2022$2.5M8 Dec 31, 2021−11.9%

Real estate and locations

ItemLatestA year beforeChange
Countries it operates in18 Dec 31, 202217 Dec 31, 20210%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$8.9M8 Dec 31, 2022$16.7M8 Dec 31, 2021−46.5%
Marketable securities, current$4.8M8 Dec 31, 2022$37.6M8 Dec 31, 2021−87.3%

Leadership

Who has led CONTRAFECT Corp, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Julia P. Gregory2014–2016
  2. Steven C. Gilman2016–2019
  3. Roger Pomerantz2019–2022

Chief financial officer

  1. Michael Messinger2019–2023

Chief operating officer

  1. Lisa Ricciardi2017
201520202025
Board members and other officers (21)

Timeline

  1. Dec 5, 20238-K Bankruptcy or receivership; Executive or director change39
  2. Nov 15, 20238-K Exit or restructuring costs; Executive or director change40
  3. Nov 8, 20238-K Listing notice or transfer41
  4. Sep 29, 20238-K Listing notice or transfer42
  5. Aug 18, 20238-K Listing notice or transfer43
  6. Aug 14, 20238-K Results of operations44
  7. Jul 25, 20238-K Other events45
  8. Jun 27, 20238-K Entered a material agreement; Unregistered sale of shares46
  9. Jun 20, 20238-K Shareholder vote47
  10. May 16, 20238-K Results of operations48
  11. Apr 18, 20238-K Listing notice or transfer49
  12. Mar 31, 20238-K Results of operations50
  13. Apr 4, 2019New chief executive Roger Pomerantz becomes CEO13
  14. Mar 23, 2016New chief executive Steven C. Gilman becomes CEO14
  15. Jul 28, 2014New chief executive Julia P. Gregory becomes CEO15
  16. Mar 5, 2008Founded CONTRAFECT Corp is founded2

Calendar

When it reported results

  1. Aug 14, 2023Reported quarterly or annual results44
  2. May 16, 2023Reported quarterly or annual results48
  3. Mar 31, 2023Reported quarterly or annual results50
  4. Nov 14, 2022Reported quarterly or annual results51
  5. Aug 15, 2022Reported quarterly or annual results52
  6. May 16, 2022Reported quarterly or annual results53
  7. Mar 24, 2022Reported quarterly or annual results54
  8. Nov 15, 2021Reported quarterly or annual results55

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

87 filings to the SEC since October 2021: 2 annual reports, 7 quarterly reports, 29 major events, 12 insider forms, 7 large holders, 30 other. The latest 20:

  1. Aug 14, 2025SCHEDULE 13G EDGAR
  2. Apr 28, 2025SEC STAFF ACTION EDGAR
  3. Feb 14, 2024SC 13G/A EDGAR
  4. Dec 5, 20238-K EDGAR
  5. Nov 15, 20238-K EDGAR
  6. Nov 14, 202310-Q EDGAR
  7. Nov 8, 20238-K EDGAR
  8. Nov 3, 2023424B3 EDGAR
  9. Nov 2, 2023EFFECT EDGAR
  10. Oct 31, 2023CORRESP EDGAR
  11. Oct 30, 2023S-1 EDGAR
  12. Oct 30, 2023UPLOAD EDGAR
  13. Oct 24, 2023S-1 EDGAR
  14. Oct 23, 2023DEFA14A EDGAR
  15. Sep 29, 20238-K EDGAR
  16. Sep 25, 2023DEF 14A EDGAR
  17. Sep 14, 2023PRE 14A EDGAR
  18. Aug 18, 20238-K EDGAR
  19. Aug 14, 20238-K EDGAR
  20. Aug 14, 202310-Q EDGAR

The 87 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How CONTRAFECT Corp is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCONTRAFECT Corp1
  • CIK0001478069
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address28 Wells Avenue, 3Rd Floor, Yonkers, NY 107011
  • Phone914-207-23001
  • Shares outstanding10,704,803 as of Nov 10, 202310
  • Public float$120.8M as of Jun 30, 20228
  • On EDGAR sinceAug 23, 20101
  • Filings545 in all: 4 (159), 8-K (109), SC 13G/A (40), 10-Q (29), 3 (28), SC 13G (20), 424B5 (17), CORRESP (14)1
    All 39 form types

    EFFECT (14), DEF 14A (12), UPLOAD (11), 424B3 (10), 10-K (9), S-8 (9), S-3 (8), POS AM (6), D (5), PRE 14A (5), 3/A (4), DEFA14A (4), FWP (4), S-1/A (4), 25-NSE (3), 5 (3), S-1 (3), S-3/A (2), 10-Q/A (1), 25 (1), 4/A (1), 424B1 (1), 8-A12B (1), CERTNAS (1), D/A (1), DRS (1), DRSLTR (1), S-1MEF (1), S-3MEF (1), SCHEDULE 13G (1), SEC STAFF ACTION (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2023
    Quarterly report (10-Q) Nov 14, 2023
    Proxy statement (DEF 14A) Sep 25, 2023
    Latest 8-K (8-K) Dec 5, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
    SEC EDGAROther events
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60